- Conditions
- Lacrimal Apparatus Disease, Salivary Gland Disease, Sjogren's Syndrome, Xerostomia
- Interventions
- Dehydroepiandrosterone
- Drug
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2041–2064
of 16,553
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Triple-negative Breast Cancer
- Interventions
- entinostat, anastrozole, diagnostic laboratory biomarker analysis, therapeutic conventional surgery
- Drug · Other · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer
- Interventions
- evaluation of cancer risk factors
- Procedure
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms
- Interventions
- Moderate-intensity and low-intensity bodywork therapy
- Procedure
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Triple-Negative Breast Cancer (TNBC)
- Interventions
- Pembrolizumab, Paclitaxel (Chemotherapy), Carboplatin
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Breast Cancer
- Interventions
- BRCA testing and questionnaire assessments
- Genetic
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Quality of Life, Communication
- Interventions
- Together After Cancer
- Behavioral
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Tampa, Florida
- Conditions
- Advanced/Metastatic HER2-negative Breast Cancer
- Interventions
- No drug
- Other
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Urothelial Carcinoma, Head and Neck Cancer, Melanoma, Bladder Urothelial Carcinoma
- Interventions
- Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells
- Genetic
- Lead sponsor
- Adaptimmune
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 8
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Buffalo, New York + 4 more
- Conditions
- Breast Cancer
- Interventions
- Patient-Participation Aid
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Shreveport, Louisiana
- Conditions
- Acute Urticaria
- Interventions
- JDP-205 Injection, Diphenhydramine
- Drug
- Lead sponsor
- JDP Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Breast Cancer-related Subclinical Lymphedema
- Interventions
- 20-30 mmHg compression sleeve and gauntlet, Manual Lymphatic Drainage
- Other
- Lead sponsor
- Mercy Research
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic HPV Related Solid Tumors, Metastatic Ovarian Carcinoma, Metastatic Soft Tissue Sarcoma, Metastatic Uveal Melanoma
- Interventions
- LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pachyonychia Congenita
- Interventions
- TD101, Normal saline (placebo)
- Drug
- Lead sponsor
- Pachyonychia Congenita Project
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Breast Cancer
- Interventions
- neratinib, placebo
- Drug · Other
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 185
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 147 more
- Conditions
- Eczema
- Interventions
- alitretinoin, Placebo
- Drug
- Lead sponsor
- Stiefel, a GSK Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 64 more
- Conditions
- Skin Disease, Pigment Disorders
- Interventions
- Part A: Baseline-Week 2, Part B: Week 4-Week 12
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ichthyosis, Pruritus
- Interventions
- Avena Sativa Skincare Regimen
- Other
- Lead sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions
- Venetoclax
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Uremic Pruritus, Pruritus
- Interventions
- nalbuphine HCl ER tablets 60 mg BID, nalbuphine HCl ER tablets 120mg BID, Placebo tablets BID
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
- Conditions
- Rheumatoid Arthritis, Lung Diseases
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 340 participants
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Vasculitis, Wegener's Granulomatosis
- Interventions
- cyclophosphamide
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1976 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acne Vulgaris
- Interventions
- Adapalene Gel, 0.1%, Tazarotene Cream, 0.1%, Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 12
- States / cities
- San Diego, California • Detroit, Michigan • Fridley, Minnesota + 9 more
- Conditions
- Advanced Solid Tumor, Lymphoma
- Interventions
- DS-3078a
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas